Journal of Neuro-Oncology

, Volume 116, Issue 1, pp 25–30 | Cite as

The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection

  • Rujun Li
  • Dongfang Tang
  • Jinshi Zhang
  • Jinding Wu
  • Ling Wang
  • Jun DongEmail author
Laboratory Investigation


The aim of this study is to investigate the inhibitory effects of 2T-P400, a derivative of temozolomide (TMZ), on glioma growth. SHG-44 and U373 human glioblastoma cell lines and SHG-44 cell subcutaneous and intracranial xenograft mouse models were used as the model system for these studies. Cell growth was analyzed using MTT assay. For intracranial glioma xenograft model, mouse brains were obtained and made as paraffin section for immunohistochemical staining. Tumor volume was calculated with this formula: tumor volume = length × width2/2. The results showed that 2T-P400 or TMZ significantly inhibits cell growth in a concentration dependent manner with the IC50 values of 12.90 ± 1.05 or 9.73 ± 2.12 μg/ml on SHG-44 cell line and 13.12 ± 0.86 or 10.13 ± 1.02 μg/ml on U373 cell line respectively. In SHG-44 cell subcutaneous xenograft model, the tumor volume of 2T-P400 or TMZ treated group was 1,062.12 ± 204.76 or 803.59 ± 110.32 mm3 respectively, which was significantly smaller than that in physiological saline (with volume of 1,968.85 ± 348.37 mm3) treated group. In intracranial xenograft model, the tumor volume of 2T-P400 or TMZ group was 6.12 ± 1.69 or 5.58 ± 1.45 mm3 respectively, significantly smaller than that in physiological saline group of 33.08 ± 6.88 mm3. Moreover, polyethylene glycol 400 (PEG400) exhibited no significant tumor growth inhibition. Our results indicated that 2T-P400 posses the same growth inhibitory effect as TMZ on glioblastoma cell lines and the subcutaneously and intracranially transplanted gliomas in xenograft mouse models. It may be a suitable alternate of TMZ for the treatment of glioma via intravenous administration route.


Temozolomide Derivative Glioma 



We thank Chemistry Institute of Tianjin Tasly Group for providing TMZ and 2T-P400. This work is supported by grants from the Chinese National Science Foundation (No. 81071766) and Jiangsu Province Science Foundation (No. BK2010227).

Conflict of interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Paravati AJ, Heron DE, Landsittel D, Flickinger JC, Mintz A, Chen YF, Huq MS (2011) Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. J Neurooncol 104:339–349. doi: 10.1007/s11060-010-0499-8 PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Minniti G, Armosini V, Salvati M, Lanzetta G, Caporello P, Mei M, Osti MF, Maurizi RE (2011) Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol 103:683–691. doi: 10.1007/s11060-010-0446-8 PubMedCrossRefGoogle Scholar
  3. 3.
    Walbert T, Gilbert MR, Groves MD, Puduvalli VK, Yung WK, Conrad CA, Bobustuc GC, Colman H, Hsu SH, Bekele BN, Qiao W, Levin VA (2011) Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. J Neurooncol 102:273–280. doi: 10.1007/s11060-010-0313-7 PubMedCrossRefGoogle Scholar
  4. 4.
    Terasaki M, Eto T, Nakashima S, Okada Y, Ogo E, Sugita Y, Tokutomi T, Shigemori M (2011) A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. J Neurooncol 102:247–253. doi: 10.1007/s11060-010-0306-6 PubMedCrossRefGoogle Scholar
  5. 5.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi: 10.1056/NEJMoa043330 PubMedCrossRefGoogle Scholar
  6. 6.
    Tsang LL, Farmer PB, Gescher A, Slack JA (1990) Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol 26:429–436PubMedCrossRefGoogle Scholar
  7. 7.
    Zhou YX, Chen XH, Xie XS, Huang YL, Xue ZM, Chen GL, Wang Z, Chen JM, Su ZP, Du ZW (2012) Orthotopic model of SHG-44 in the enhanced green fluorescent protein nude mouse. J Neurosci Res 90:1814–1819. doi: 10.1002/jnr.23052 PubMedCrossRefGoogle Scholar
  8. 8.
    Wu N, Wu GC, Hu R, Li M, Feng H (2011) Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128. Acta Pharmacol Sin 32:345–353. doi: 10.1038/aps.2010.220 PubMedCrossRefGoogle Scholar
  9. 9.
    Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O’Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771PubMedGoogle Scholar
  10. 10.
    Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593. doi: 10.1054/bjoc 2000.1316PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Brandes AA, Ermani M, Basso U, Paris MK, Lumachi F, Berti F, Amista P, Gardiman M, Iuzzolino P, Turazzi S, Monfardini S (2002) Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. Oncology 63:38–41. doi: 10.1159/000065718 PubMedCrossRefGoogle Scholar
  12. 12.
    Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382PubMedCrossRefGoogle Scholar
  13. 13.
    Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA (2002) Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20:1383–1388PubMedCrossRefGoogle Scholar
  14. 14.
    Chang SM, Theodosopoulos P, Lamborn K, Malec M, Rabbitt J, Page M, Prados MD (2004) Temozolomide in the treatment of recurrent malignant glioma. Cancer 100:605–611. doi: 10.1002/cncr.11949 PubMedCrossRefGoogle Scholar
  15. 15.
    Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. doi: 10.1056/NEJMoa043331 PubMedCrossRefGoogle Scholar
  16. 16.
    Dario A, Tomei G (2006) The safety of the temozolomide in patients with malignant glioma. Curr Drug Saf 1:205–222PubMedCrossRefGoogle Scholar
  17. 17.
    Birner A (2003) Pharmacology of oral chemotherapy agents. Clin J Oncol Nurs 7:11–19. doi: 10.1188/03.CJON.S6.11-19 PubMedCrossRefGoogle Scholar
  18. 18.
    Derkaoui N, Said S, Grohens Y, Olier R, Privat M (2007) PEG400 novel phase description in water. J Colloid Interface Sci 305:330–338. doi: 10.1016/j.jcis.2006.10.008 PubMedCrossRefGoogle Scholar
  19. 19.
    Zhang H, Gao S (2007) Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro. Int J Pharm 329:122–128. doi: 10.1016/j.ijpharm.2006.08.027 PubMedCrossRefGoogle Scholar
  20. 20.
    Chen J, Zhang Y, Wu Y (1994) Expression of the O6-methylguanine-DNA methyltransferase gene in eight human tumor cell lines. Chin Med Sci J 9:143–146PubMedGoogle Scholar
  21. 21.
    Zhang J, Stevens MF, Laughton CA, Madhusudan S, Bradshaw TD (2010) Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 78:103–114. doi: 10.1159/000306139 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Rujun Li
    • 1
  • Dongfang Tang
    • 1
  • Jinshi Zhang
    • 1
  • Jinding Wu
    • 1
  • Ling Wang
    • 1
  • Jun Dong
    • 1
    Email author
  1. 1.Department of NeurosurgerySecond Affiliated Hospital of Soochow UniversitySuzhouChina

Personalised recommendations